Moderna looks ahead, after potential $2.25 billion settlement announced
Moderna faces a turning point after settling a patent dispute and gaining FDA review for its flu vaccine, shifting focus towards oncology.Summary
Moderna is navigating a critical juncture following a potential $2.25 billion settlement with Arbutus Biopharma and Genevant Sciences, and the FDA’s reversal to review its flu vaccine. While initial concerns about the settlement’s cost proved overblown, with the company’s stock rising, Moderna is strategically pivoting away from COVID-19 vaccines towards oncology, rare diseases, and norovirus vaccines. Experts like Myles Minter suggest diversifying into oncology, partnering with Merck, could lead to financial stability.
This shift is particularly important given increased scrutiny of mRNA technology and vaccines from federal officials, including Health and Human Services Secretary Robert F. Kennedy Jr. While the future of Moderna’s infectious disease vaccines in the US remains uncertain, the company is seeing more receptive regulatory environments in other countries, like Europe.
Promising clinical trial results for a melanoma vaccine, combined with Merck’s Keytruda, offer a potential “redemption arc” for Moderna, with oncology potentially becoming its primary revenue driver. Investors are optimistic, but success hinges on pivotal trial results and navigating the evolving landscape of vaccine acceptance and regulation.
(Source：The Boston Globe)